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Abstract
Modern health care organizations, e.g., tissue banks, require a resource-based 
view (RBV) for an efficient stimulation of innovation, productivity, and per-
formance, especially in the context of laboratory management and new product 
development. High quality advanced therapy medicinal products (ATMPs) are 
expected to bring important health benefits; therefore, their production has to be 
performed in accordance with good manufacturing practice (GMP). Although there 
are no precisely defined criteria for quality control/evaluation methods of obtained 
ATMPs, all aspects of pharmaceutical quality of ATMPs’ development, manufactur-
ing, distribution, inspection, and review processes ought to be strictly fulfilled. 
Explicit performance management and production regimes in accordance with 
pharmacopeia and RBV philosophy have been proposed in this chapter.
Keywords: resource-based view, advanced therapy medicinal products, tissue bank, 
good manufacturing practice, lean management
1. The change of paradigm
An innovative way of hospital management appeared in the 1990s. Methods 
originating from the industry and known as lean management and Theory of 
Constraints (TOC) have proven surprisingly adequate in health care environment. 
These helped to overcome the problems of many hospitals facing severe issues and 
as a result requiring turnaround.
Effective management of the organization has to be holistic in nature and focus 
exclusively on the point of view of client/patient instead of unit managers. The 
effectiveness and process synchronization have to be also looked upon from the same 
perspective. Management approach aiming at local optimizations traps the manag-
ers ultimately leading to underperformance of the organization as a whole, witch 
hunt and frustration from the very bottom to the top of the organizational ladder. 
Moreover, most of the employees including top managers are not fully aware of the 
structure of processes in their company. These processes do not fit the most com-
monly applied management practices. In their nature, these are horizontal and not 
vertical like the structures of most of the organizations [1].
Biochemical Testing - Clinical correlation and Diagnosis
2
The term “lean management” has been first formulated by the American 
researcher John Krafcik who has been investigating the reasons behind competitive 
advantage of Japanese automobile industry over its American counterpart. Krafcik 
has been particularly impressed by the Toyota Production System (TPS), which has 
been developing in Japan from mid-1940s.
Essentially, lean system could be defined as an elimination of waste and respect 
to all of the employees organization-wide. The goal of the organization is to deliver 
added value to the patient/client/payer. Added value is generated when any activ-
ity that delivers tangible results in the process is performed correctly the first time 
and for which the patient/client/payer is ready to pay. All the rest is regarded as 
waste. There are seven types of waste defined by the TPS originator—Taiichi Ohno. 
Detailed description is outside the scope of this book, but an interested reader will 
easily find it outlined in many available resources [2].
The set of tools and techniques applied in lean is usually presented as the so-
called Toyota House or Lean House. The fundaments of the house comprise 5S—the 
system of creating and maintaining a neat and clean work environment, continuous 
improvement, standard work, balanced distribution of the job, and visual controls. 
All of these elements are crucial; nevertheless, 5S and standardized work require 
closer explanation.
The majority of organizations do not realize how much waste is hidden in their 
current processes. There is an abundance of unnecessary tools, equipment, excess 
inventory, documentation, etc., in any hospital. All these obscure the real problems. 
Any attempt to optimize the processes without launching 5S at the very beginning is 
doomed to fail as the main issues will stay hidden behind the visible surface.
Standard work in lean is different from what is usually meant by the notion. 
Standardization is the best presently known way of performing a certain task. If 
the employees develop a better, safer way, the standard work can be changed almost 
immediately. This is different from the traditional approach relying on rigid rules, 
which are almost impossible to change. Actually, lean is a scientific method based 
on continuous experiments, which make it extremely flexible, and ensures involve-
ment of the employees on all the levels.
Two walls of the Toyota House can be distinguished. The first one is continu-
ous flow, which concentrates on elimination of delays as well as right care in the 
right time in the right place. The second one is a quality approach, focusing on 
error detection, preventing errors at the very source, and involving the employees 
in problem-solving. The most important rule is to ensure that no witch hunt takes 
place. Instead, employees providing information about the existing and possible 
issues and implementations of related solutions should be rewarded.
Finally, the roof comprises the ultimate goals: health, safety, staff morale, and 
patient satisfaction.
Unfortunately, the term “lean” has been misinterpreted, mainly in the USA, and 
used in the form of practices involving layoffs and increased work burden. As a 
result, it has lead to pathologies that are in no way connected to the Japanese ideas. 
The authors would like to stress that the aforementioned mismanagement has noth-
ing in common with genuine lean, which is based directly on TPS.
Theory of Constraints emerged at the beginning of the 1980s, when the Israeli 
physicist, Dr. Eliyahu Goldratt who became interested in the production planning 
processes, published his first book on the subject in the form of a bestselling busi-
ness novel The Goal [3]. Goldratt claimed that every organization has its own main 
constraint, either internal or external, and proposed a set of five steps called the 
Process of Ongoing Improvement (POOGI) to handle these issues accordingly. The 
aforementioned steps are:
3Resource-Based View of Laboratory Management: Tissue Bank ATMP Production as a Model
DOI: http://dx.doi.org/10.5772/intechopen.86561
• Identify the constraint,
• Exploit the constraint—ensure that the constraint is operational all the avail-
able time,
• Subordinate all the resources within the organization to the requirements of 
the constraint,
• Elevate the constraint, i.e., widen it, and
• If the constraint has been broken, identify the new one and start the process all 
over again, but be aware of the inertia.
Over the following years, Goldratt developed the applications of the TOC in 
various areas like project management, sales, marketing, and people management. 
In the 1990s, he introduced the TOC thinking processes—a set of tools aimed at 
enhancing the analysis of the problems and building solid, logical, time-proven 
solutions. Today, TOC has found its applications in many different areas both in 
manufacturing and in services like logistics, strategy, health care, education, and 
resocialization [4].
It has to be stressed that both lean and TOC—if they are to be implemented 
the proper way—have to be a company-wide effort closely supervised and led by 
the top management. Both clinical and nonclinical departments must be taken 
into account. Obviously, the positive cultural change of the organization will 
follow as an ultimate result of the implementation. The task is by no means easy, 
but the payoffs are well worth it. Potential benefits include 20–80% of produc-
tivity improvement, reduction of unnecessary length of stay, and significant 
reduction in inventory and space, and savings counted in millions of  
local currency are not uncommon if the methods are applied properly and  
given sufficient time [5]. One has to remember that both methods advocate  
continuous and growing improvement and are therefore not a one-time 
initiative.
Neither lean nor TOC is meant to replace the golden medical standards or the 
standards of pharmaceutical production like GMP. They are rather complementary 
tools and techniques, paving the way for the existing standards to rise to new 
levels.
Dr. Stanislaw Sakiel Burn Treatment Centre (CLO) based in Siemianowice 
Śląskie, Poland, is a top hospital specializing primarily in the treatment of 
burns and chronic wounds. CLO has been a pioneer in application of TOC and 
lean in hospital management since early 2016. According to the knowledge of 
the authors, it is the only hospital in Poland where the system not only is still 
functioning but also delivers constantly better results. The Bank of Tissues has 
been among the first units where the approach has been applied. The project 
was initiated in 2016. Despite the fact that GMP was already in place, it soon 
became apparent that there is still a huge room for improvement. The decision 
to implement 5S quickly delivered results. Process mapping followed, together 
with visible changes in the flow in local production site. Today, the flow is faster, 
job is better organized, and the breaks are sporadic instead of being a norm. 
Improved communication with the operating theater resulted in more on-time 
deliveries and less unnecessary additional transports. This in turn contributed to 
shorter surgical procedures and better overall conditions for patients and medi-
cal personnel alike.
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2.  Resource-based view (RBV) approach in health care organizations 
and tissue bank laboratory management
2.1 Resource-based view framework for health care organizations
The resource-based view (RBV) is a theoretical framework used to study and 
explain the competitive behavior of organizations [6, 7] that emerged in 1980s 
and 1990s, after the major works published by Barney, J. Firm Resources and 
Sustained Competitive Advantage, Prahalad and Hamel The Core Competence of the 
Corporation, and Wernerfelt, B. The Resource-Based View of the Firm. Since then, 
RBV approach has been widely used and appreciated in the management of pri-
vate organizations. However, it may also bring a promising framework to imple-
ment in the context of large-scale quality improvement within the public health 
care entities. Although these theories may be novel for the health management 
field, including models of strategic management originally developed for private 
sector firms, their application within publicly funded settings may be problematic 
or require customization, but nevertheless provide interesting insights [8]. It 
may provide a sustainable solution to manage quality driven, highly complex, 
and environmentally turbulenced settings such as tissue bank laboratories. RBV 
approach may be the answer to maximize growth, quality, and performance in a 
way to cope with modern, rapid technological changes and competitive medical 
environments.
The tissue banking sector quality improvement efforts take place in interor-
ganizational networks rather than in a large, vertically integrated organization. 
Therefore, tissue bank managers encounter significant difficulties in understand-
ing high organizational complexity that cannot be reduced to simple cause-effect 
relations or one variable [8]. The challenge is not only to be in compliance with 
applicable codes and quality regulations of good manufacturing practice (GMP), 
state regulatory agency, or pharmaceutical regulatory requirements, but also at 
the same time to optimize your business operations and standardize workflows in 
processing laboratories. Navigating through this complicated regulatory milieu and 
at the same ensuring efficient manufacturing process along with sensible business 
cost balance may require a RBV theoretical framework. Resource-based view and 
regulatory compliance are not mutually exclusive but should be combined to deliver 
excellent performance improvements and complex approach to stimulate organiza-
tion’s competitiveness, productivity, and innovation.
2.2 RBV model
The RBV resource approach assumes that the success of the organization lies 
within the organization itself, or to be exact, in its valuable, intangible, and not 
perfectly imitable resources (VRIO condition) allowing it to achieve a sustainable 
competitive advantage [9]. Resource-based view (RBV) analyzes and interprets 
resources of the organizations to understand how organizations achieve sustain-
able competitive advantage. The RBV focuses on the concept of difficult-to-imitate 
attributes of the firm as sources of superior performance and competitive advantage 
[10, 11]. It takes an ‘inside-out’ view of firm-specific perspective on why organiza-
tions succeed or fail in the market place [12]. According to this approach, resources 
are given the superior role in achieving higher organizational performance. The RBV 
model presents some critical assumptions regarding resources, which are about to be 
met, in order to obtain efficient manufacturing process in line with regulatory com-
pliance. The first stage of the RBV model categorizes resources within the organiza-
tion into two basic types: tangible and intangible resources. The literature categorizes 
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resources also into three main categories: tangible resources, intangible resources, 
and capabilities [13]. Capabilities refer to the skills organization possesses to coordi-
nate the resources (i.a., teamwork, organizational culture, and trust); however, they 
are not clearly owned and difficult to measure. For the purpose of the RBV model 
in this paper, the author included capabilities into tangible and intangible resource 
category (Table 1).
Tangible resources belong to the organization and can be divided into fixed 
assets (i.e., tissue bank facilities, land, laboratory machinery, clean room systems, 
and furniture) and current assets including, i.a., capital equipment, laboratory 
equipment, inventory, and financial means. Such assets are also referred to as 
property-based resources [6]. Other divisions of tangible resources include also 
categories of physical and financial assets [14].
Intangible resources, also referred to as knowledge-based resources [15], consist 
of intellectual property and include, i.a., operational knowledge of the laboratory 
employees, process knowledge, procedures, accumulated experience, patents, tissue 
bank brand recognition, community relationship, trademark, and legal agreements. 
They can be further divided into infinite and finite intangible assets (Figure 1).
Tangible and intangible resources can be further grouped into various sub-
categories. One of them was first presented by Barney [13] and included physical 
resources (physical, technological, plant, and equipment), human capital resources 
(training, experience, and insights), and organizational capital resources (formal 
structure). An example of broader classification of resources and capabilities of a 
tissue bank can be found in Table 1.
According to RBV, not all resources of the firm will be strategic and, hence, 
sources of competitive advantage. Competitive advantage occurs only when there is 
a situation of resource heterogeneity and immobility [16]. The resource heterogene-
ity implies that organizations have varying capabilities and possess unique bunch 
of resources allowing them to design different strategies to obtain competitive 
advantage. Resource immobility may be understood as inability of competing firms 
to obtain resources from other firms. If the resource is not perfectly mobile  
Table 1. 
Examples of tissue bank tangible and intangible resources and capabilities.
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(i.e., the resource is not free to move between firms, or if a firm without a resource 
faces a considerable cost burden in developing, acquiring, or using it that a firm 
already using it does not), then the resource is likely to be a source of sustained 
competitive advantage [16].
In order for the resource to provide sustainable and desirable performance, 
VRIO framework criteria must be fulfilled. The original tool VRIN was described by 
Barney [10] in his work Firm Resources and Sustained Competitive Advantage and was 
later improved by Barney to VRIO in Looking Inside for Competitive Advantage (1995).
1. Valuable (V): a resource is considered valuable when it provides strategic 
value to organization, enabling it to exploit opportunities or defend against 
threats. The resource that is unable to meet this criterion leads to competitive 
disadvantage.
2. Rare (R): rare resources, hard to obtain by competitors, grant temporary 
competitive advantage. The resource must be rare enough to design and 
execute unique business strategy in comparison with other organizations on 
the market.
3. Imperfect imitability (I): the resource leading to competitive advantage must 
be costly to imitate for other organizations that do not have it. The resource 
may also be hard to imitate not only because of financial reasons but also 
because of difficulties in acquiring it, its complexity, causal ambiguity, or even 
historical conditions.
4. Non-Substitutability (N): it is impossible for a competitor to substitute 
or replace a certain resource by other or alternative resource/Organized to 
Capture Value (O): it is the task of the organization to be able to organize its 
management systems, processes, and procedures in a way to fully realize the 
Figure 1. 
RBV model.
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potential of its unique resources. Therefore, the resource itself does not confer 
any value to the company; it is crucial to organize the company allowing it to 
achieve not only temporary but also sustained competitive advantage.
The VRIO framework may therefore be a crucial strategic analysis tool uncov-
ering resources and capabilities that give organizations a long-term competitive 
advantage. An example of VRIO analysis for tissue bank can be found in Table 2.
2.3 Summary
Internal resources and capabilities determine strategic choices made by firms 
while competing in their external business environment [15]. As resource require-
ments in health care organizations must be carefully managed due to cost con-
straints, RBV approach along with VRIO resource analysis adaptation to tissue bank 
not-for-profit settings seems intuitively sound. Resource-based view can ensure 
sensible balance between complying quality regulations that govern tissue banks 
and optimizing processing practices. Examining and identifying unique (valu-
able, rare, and costly to imitate) organizational resources through RBV and VRIO 
framework may deliver simple but excellent performance improvements. Finding 
out if the entity is organized to exploit the resources and protecting them may lead 
to better financial results as control of superior and unique resources is necessary to 
establish a cost advantage, which leads to profitability [14]. Finally, constant review 
of VRIO resources and capabilities enables organizations to establish clear-cut 
sustainable competitive advantage and growth.
3. Activity and documentation of a tissue bank
The activity of a tissue bank may be limited to the preparation of biostatic (radia-
tion sterilized) and biovital (living) grafts using documented and proven procedures. 
In this regard, a tissue bank operates under a Ministry of Health License and must 
demonstrate the implementation of a quality assurance system that meets the require-
ments of the Law of July 1, 2005, on the collection, storage, and transplantation of 
cells, tissues, and organs as amended (Journal of Laws 2017 item 1000). The regulation 
Table 2. 
Examples of VRIO analysis: ADM patent.
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contains the basic documents that a tissue bank quality system must include; however, 
some of the mentioned documents seem to be obsolete. The basic documents used 
in a tissue bank are standard operating procedures (SOPs). SOPs must describe the 
requirements regarding primarily the processes and activities related to the collection 
of cells or tissues, their acceptance, processing, storage, distribution, transport, as 
well as monitoring the condition of cells or tissues on their way from the donor to 
the recipient. Standard operating procedures should specify the medical devices and 
materials that have direct contact with cells or tissues. The criteria for the qualification 
and selection of the cell or tissue donor and the criteria for excluding the deceased 
donor, including the objection against the collection of tissues, must be clearly 
defined. Standard operating procedures should describe the method of cell or tissue 
collection, detailing the data necessary for the identification of the entity arranging 
the tissue collection and the data regarding the collection itself so as to ensure full 
traceability of the collected cells or tissues. The procedures must specify the means of 
transporting the collected cells or tissues and their acceptance into the tissue and cell 
bank. The quality system procedures in a tissue bank must specify how to identify and 
secure cells or tissues during transport, and describe the stage of acceptance of tissue 
and cellular material into the bank, specifying the information on:
The way in which cells or tissues are accepted into a tissue and cell bank, taking the 
following into account:
a. The common understanding of the purpose of the collected cells or tissues
b. Results of medical examinations, specialist examinations, and laboratory tests
c. Documented criteria of donor selection performed by an authorized person
d. Documented transport, packaging, and labeling conditions
e. The assessment of the quality of the cells or tissues accepted into the  
tissue and cell bank
f. The method of dealing with cell or tissue transplants that do not conform 
with the specification and have incomplete test results and unacceptable 
quality or defects
g. The course of quarantine from the time of acceptance of cells or tissues into 
the tissue and cell bank until they are released for processing or withdrawn
The next step, which must be included in standard operating procedures, is the 
processing of cells or tissues. These procedures must take into account the 
requirements regarding the following elements of all cell or tissue type process-
ing: labeling, processing conditions, and ongoing evaluation of the processing 
operations in order to ensure the safety and quality of the cells or tissues being 
processed. The SOPs must describe the manner of approval and documentation 
of the changes in the processing operations. A cell or tissue identification system 
must be developed and described at every stage of the processing to distinguish 
between authorized products and unauthorized products. The infected cell or 
tissue removal or withdrawal procedures must be developed and described to 
prevent infection of other processed cells or tissues, the processing products, 
environment, or personnel.
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The SOPs must include the following:
• The grace period conditions after the processing of cells or tissues
• The method of cell or tissue sterilization
• The grace period conditions after the sterilization of cells or tissues
• The manner of storing the processed cells or tissues and releasing them for 
distribution after the grace period
Another stage that must be included in the quality system is the storage of cells 
or tissues after processing. Procedures in this regard must specify the requirements 
for the following:
• Separate storage conditions and maximum storage time for each cell or tissue 
type, taking into account the possibility of deterioration of the cell or tissue 
properties in the course of storage
• Separate storage conditions and maximum storage time for each type of 
product derived from the processed cells or tissues, taking into account the 
possibility of deterioration of the product properties
• The development of a cell or tissue inventory and identification system at each 
storage stage
Standard operating procedures for the distribution of cells or tissues determine 
the requirements regarding labeling of materials intended for distribution as well as 
transport criteria and conditions. The scope of standard operating procedures must 
also include the monitoring of the quality of cells or tissues on their way from the 
donor to the recipient.
A very important aspect is to define the manner of recording significant adverse 
events and significant adverse reactions associated with the collection, testing, pro-
cessing, storage, distribution and transplantation of cells or tissues, their reporting, 
and elimination of the reasons for their occurrence.
The documentation of the quality system must also contain the operating 
manuals specifying the applicable documentation, including types of documents, 
their keeping and circulation in the tissue and cell bank, and the manner of keeping 
records of specific activities performed in a tissue bank. The documentation must 
also contain reporting forms and donor cards.
The described quality system concerns procedures regarding tissue and cell 
banking. If a tissue bank additionally produces advanced therapy medicinal 
products (ATMPs) using the hospital-exemption advanced therapy medicinal 
product (HE-ATMP) production procedure, two complementary systems must 
be developed. Becoming a producer of hospital-exemption advanced therapy 
medicinal products, the tissue bank must additionally implement the good man-
ufacturing practice (GMP) quality system certified by the Main Pharmaceutical 
Inspectorate.
The system requires the development of documentation necessary to meet the 
requirements of the GMP quality system. The basic document containing the pro-
ducer’s characteristics is the site master file describing the activities of the production 
authorization holder related to the good manufacturing practice.
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The GMP documentation must also include the following manuals:
• Specifications describing in detail the requirements for a medicinal product or 
material used or obtained in the production process. They constitute the basis 
for quality assessment.
• Production recipes, processing and packaging instructions, and testing 
manuals. This documentation must provide details of all the output materi-
als, devices, and computer systems used. All instructions regarding the 
processing, packaging, sampling, and sample testing must also be specified 
in detail.
In-process control and process control in real time (PAT—process analytical 
technologies) that are used in the process must be specified along with the accep-
tance criteria:
• Procedures: standard operating procedures (SOP) determining the manner of 
operation execution
• Protocols presenting the manuals and records of the concerned operation 
execution
• Contractual agreements referring to arrangements between the client and the 
contractor for commissioned activities
The GMP system defines the types of records and reports:
• The records provide evidence of actions taken to demonstrate compliance 
with the manual, e.g., activities, events, tests, and, in the case of batch 
production, the history of each batch of a medicinal product, including its 
distribution. Records contain raw data that are used to create other entries. All 
data used as the basis for quality activities should be defined as raw data.
• The analytical certificates provide a summary of the medicinal product 
sample or material test results including the assessment of compliance with 
a given specification. Alternatively, the certification can be based entirely 
or in part on real-time process control (summaries and deviation reports) 
for a batch associated with real-time batch control (PAT—process analytical 
technologies), with parameters and measurements that must comply with the 
approved documentation attached to the marketing authorization.
• The reports document the execution of individual tests, projects, or studies as 
well as results, conclusions, and recommendations.
In the GMP quality system, it is necessary to develop and supervise the docu-
mentation, which is defined in the good documentation practice.
It includes the following recommendations:
• The manually entered data must be clear, legible, and impossible to delete.
• The records must be made or supplemented in the course of execution of each 
activity in such a way that all important activities related to the production of 
medicinal products are reproducible.
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• Every change of a record in a document should be signed and dated, and the 
means of introducing the change must enable the original information to be 
read. The reason for the change must be provided in justified cases.
In order to properly archive documents, the relationship between the record 
and the production activity should be clearly defined as well as the place where the 
record has been entered.
It is also necessary to have the properly approved and dated specifications of 
starting and packaging materials as well as the finished products.
The following documents should also be developed:
• Production recipes and production manuals
• Packaging instructions
• Batch production records
• Batch packaging records
The acceptance of each delivery of any starting material (including bulk prod-
ucts, intermediate products, and finished products) of any direct, external, and 
printed packaging material requires written procedures and records. It is necessary 
to develop written procedures for material and product testing at various stages of 
production, describing the methods and equipment used. The executed tests should 
be documented.
As part of the GMP system, written procedures for releasing or rejecting 
materials and products, including the certification of the finished products by the 
qualified person, must be developed. All entries must be available to the quali-
fied person. The developed system must immediately identify deviations and any 
changes implemented in the critical data.
The distribution records of each manufactured batch of medicinal product must 
be kept and stored in order to withdraw a series from the market if necessary.
The system also requires the development of written procedures, programs, 
protocols, reports, and related records regarding undertaken actions or final 
conclusions. These procedures should include the following:
• Process, equipment, and system validation and qualification
• Device assembly and calibration
• Technology
• Maintenance, cleaning, and disinfection
• Personnel issues, including a list of specimen signatures, and training in 
respect to the requirements
• Technical issues, protective clothing and hygiene, as well as the verification of 
the effectiveness of the training sessions conducted
• Environmental monitoring
• Pest control
Biochemical Testing - Clinical correlation and Diagnosis
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• Complaints
• Withdrawal from the market
• Returns
• Change control
• Explanatory proceedings regarding deviations and nonconformities
• Internal audits regarding the quality and observing the good manufacturing 
practice
• Record summaries
• Audits at suppliers
The producers must provide clear and understandable operating instructions for 
the main production and control equipment. They must keep logs of the master and 
critical control equipment, production equipment, and areas in which production 
processes take place. There must be records regarding each area, device, method, 
calibration, maintenance, cleaning, or repair introduced in chronological order, 
dated and signed by the personnel performing these activities. A list of quality 
management system documents should be kept.
4.  Quality and risk management in compliance with GMP and with 
reference to RBV
As described above, the cells were qualified by the European Medicines Agency 
as advanced therapy medicinal products (ATMPs), so their production is subject to 
good manufacturing practice (GMP) [17]. The ATMP implementation is therefore 
not only technologically complex but also strictly regulated by national and 
European laws. GMP, although it is the legal basis, is only a part of quality manage-
ment at tissue banks [18]. By definition, resource-based view contains all the 
principles of good manufacturing practice. If the quality of the delivered product is 
defined by us as meeting the requirements and expectations of patients, simple 
observation of the GMP does not guarantee that these requirements will be met 
[18]. It seems that only the combination of GMP with the ISO 9001 standard, the 
RBV approach, and lean management enables a comprehensive approach to man-
agement, including quality and risk management. ATMP production is special and 
requires a rigorous and carefully monitored bioprocess to control the intrinsically 
complex and variable nature of the substance, especially since some ATMPs can be 
combined with medical devices, such as biodegradable matrices or scaffolds [19]. It 
should also be mentioned that material collection from a patient takes place in a 
hospital that is not a GMP-controlled environment, which additionally contributes 
to the increased variability of this stage [20] and leaves room for other management 
techniques, such as RBV and lean. A better understanding of graft production 
management requires risk analysis, including its identification, assessment, and 
control. The risk is determined by the likelihood of damage and the consequences of 
this damage. The risk associated with the quality of the advanced therapy medicinal 
product/tissue is one of the components of the total risk arising from the produc-
tion and use of the graft. This indicates the need to extend quality management 
13
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with a resource approach. Product quality must be maintained throughout the 
entire production cycle and must allow identification and control of potential risks 
associated with development, production, and transplantation. The quality risk 
management principles include development, production, distribution, process 
reviews, and validations. An important element of the quality system resulting 
from GMP is the process of corrective and preventive actions (CAPA), which refers 
to deviations, i.e., events departing from the approved procedures or instructions. 
An example would be a change of the culture incubator during the process or 
allowing the tissue to be packaged without obtaining the results of quality control 
analyses. These types of activities are sometimes undertaken to rescue the medicinal 
product (graft) or to maintain the continuity of cell culture; however, the area of 
their application ends at the stage of production of the medicinal product. The 
initial stage in the CAPA process is to clearly define the problem, i.e., register  
the deviation and provide its short description containing the scope and area of the 
occurrence of the irregularity and to indicate the leader of the explanatory actions, 
who will be responsible for carrying out the entire explanatory procedure. At this 
stage, it must be added that the idea of corrective and preventive action implemen-
tation is not to blame anyone but to continuously improve the production process 
and the quality of grafts. In determining the actual or most probable cause of an 
adverse event, the following elements should be taken into account: the equipment 
and materials used, validity, feasibility and comprehensibility of procedures, the 
design of the entire process (including its bottlenecks), the level employee qualifi-
cations, software, and external factors. Any additional resources that may poten-
tially have an impact on the adverse event that has occurred are also identified and 
documented. After preparing a list of probable causes, the information and data 
collection must ensue to be used to draw conclusions about the possible cause of the 
event. Then, the explanatory actions are implemented and the reasons for the 
deviation are identified. Repair/corrective actions and their implementation are also 
specified, and all these actions should be described in order to later verify the 
effectiveness of the steps taken. Then, there is risk communication, which is a 
process of sharing risk information and risk management methods between deci-
sion-makers and other parties. The parties exchange information at each stage of 
the risk management process. If the explanatory actions do not show the reason for 
the deviation, a quality risk assessment should be performed. A number of com-
monly accepted and well-defined methods and processes of risk analysis and 
quality risk management have been developed. Risk control in turn involves actions 
that introduce decisions in the area of risk management. The purpose of risk control 
is to make decisions, which lead to risk reduction to an acceptable level. The contri-
bution of work devoted to risk management should be proportional to the risk 
weight. Preliminary hazard analysis (PHA) is an analytic tool based on the applica-
tion of previous experience or knowledge about the threat or failure to identify 
future threats (Annex 20 GMP). One of the PHA variations is brainstorming, 
during which the expert group asks “what if” questions to identify the impact of 
individual elements on the production process and formulate recommendations for 
the actions to be taken. The quality of the results obtained using this method 
depends to a large extent on the experience and knowledge of the participants [20]. 
The hazard and operability studies (HAZOP) method of analysis was developed in 
the 1960s. Like the PHA, it is a systematic method; however, it requires more 
detailed information. The HAZOP method uses a predefined set of guiding words to 
describe the parameters, which leads to the creation of a pair of words that is 
referenced to a point in the process that can potentially fail. As a result of using this 
method, a table is created that includes situations, which can cause a failure, 
together with its consequences and specific causes. However, this is a 
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time-consuming and labor-intensive method and as such it generates considerable 
costs [20]. The process map is a technique based on a graphical representation of the 
functioning of a set of processes and their mutual relationships. The fault tree 
analysis (FTA) has been developed for the aviation industry and is a deductive 
method that assumes the occurrence of a defect in process functionality and can 
link multiple causes to identify the cause-and-effect chain. Failure mode and effects 
analysis (FMEA) is mainly focused on the optimization of the product and is 
particularly recommended in the situation of new product introduction because it 
allows for the recognition of the potential interfering factors. As a result of this 
quantitative method, we obtain the so-called risk priority number (RPN) and 
information about strong and weak points of production. The criticality of the 
defect is calculated, and the higher the calculated parameter, the greater the risk 
associated with the defect. After identifying the risks and weaknesses of the process 
and their characterization, decisions should be made on which risks should be 
reduced and which should be observed or eliminated. Controlling risks is a techno-
logical and economic challenge. Before making any changes, an assessment must be 
performed to ensure that the proposed change will not cause any new or unex-
pected risks. The fact that a change is inevitable makes it a critical factor, especially 
in GMP and ISO environments, where inappropriate or “uncontrolled” changes can 
affect patient safety and public health. For this reason, the concept of change 
control is closely related to compliance with GMP and ISO, where any changes in 
production and processes must be controlled. Change control procedures must be 
recorded in order to standardize the workflow, especially at key stages such as 
collecting material outside the production environment. The “uncontrolled” change 
refers to modifications made without verification and approval by the quality 
control manager and in special cases also the hospital management. In GMP and 
ISO environments, strict adherence to approved policies and procedures is a key 
factor in maintaining production efficiency in a controlled state, and change control 
is critical. Changes are subject to review and approval by the quality control unit. To 
summarize, GMP is a formalized procedure and imposes a heavy burden on the 
producer of transplants, and while compliance is a required minimum, it is not 
enough to ensure the right quality of using the manufactured products [18]. The 
specificity of risk management in the aspect of GMP consists in focusing on poten-
tial failures in the production of transplants and their safety for the patient. RBV 
refers to a broader management area including risk management at the time of 
collecting cellular material and its transplantation as well as the patient’s fate. 
However, some authors point to limitations in the application of resource manage-
ment in the public health service [8] due to the complex nature of such entities. 
Lean management possesses tools that are able to systematize it [21].
5. Production management
The tissue bank is the place for graft preparation for the treatment of patients 
with severe burns and chronic wounds. As already mentioned, the preparations 
produced in our bank are biostatic grafts, which are subject to radiation sterilization 
and live cell transplants, produced under sterile conditions. Due to the specificity 
of the products manufactured in the laboratories, appropriate, supervised envi-
ronmental conditions must be ensured. For this purpose, we use “clean rooms,” in 
which, thanks to the use of special HEPA filters and laminar air vents, it is possible 
to obtain the appropriate class of air purity. The highest class achieved in our bank 
is air purity class A achieved under the laminar chamber, where the amount of 
particles and microorganisms generated during operation should be zero. In order 
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to provide such sterile and dust-free conditions in air purity class A, the rooms 
located on the way to a class A clean room must meet a series of criteria. The main 
one is the maintenance of a pressure cascade, which means that in order to get to 
a class A clean room, you have to go through several airlocks separating neighbor-
ing rooms of the following purity class: gray (of the least air purity) D, C, and 
B. Positive pressure is maintained in each airlock in relation to the previous lock, 
employees wear dust-free and sterile clothes and gloves, and, finally, in the class B 
air purity room, they put on a sterile dust-free clean room suit covering their entire 
body. All these precautions are necessary because we want to protect the product we 
manufacture, i.e., the advanced therapy medicinal product in the form of cultured 
skin cells. The cultures that we prepare are supervised by the Main Pharmaceutical 
Inspector; therefore, as mentioned above, they must be prepared in accordance 
with good manufacturing practice (GMP). The requirements that we must meet 
in order to culture cells for a burn patient make all the preparations leading to 
the process initiation strategic. It should be noted that employees and resources 
(reagents and consumables) in the laboratory are in a constant state of readiness. 
At the same time, we are not able to estimate with 100% certainty whether, at a 
given time, we are going to culture cells at all and, if so, for how many patients. The 
unpredictability of the production process (cell culture) in the face of the risk of 
expiry of reagents necessary for maintaining production continuity means that a 
compromise must be found consisting in the continuous maintenance of small-scale 
stock of culture materials. The greater part of consumables used in the preparation 
of medicinal products is highly specialized and is not widely available, and the 
delivery of a larger quantity often takes a long time. Therefore, ensuring constant 
availability of materials seems to be one of the solutions enabling continuity of pro-
duction. However, lean management requires keeping losses to a minimum, which 
is, in a way, contrary to the GMP assumptions making production halt risk minimi-
zation a priority. A common-sense approach should therefore be applied translating 
into ensuring the minimum amount of reagents that is sufficient to maintain the 
continuity of production, even in the case of mass events, such as an explosion in a 
coal mine, when mass production of cellular grafts must be available immediately.
In the case of maintaining sterile environmental conditions, it is also important 
to systematically and periodically perform cleaning and disinfection of rooms 
according to the adopted schedule. It is also necessary to permanently perform 
environmental monitoring: continuous monitoring of the amount of particles in 
class B rooms, as well as microbiological tests of air and clean room surfaces, carried 
out according to schedule. Control and supervision are also applied to devices used 
for cell culture and the conditions prevailing in them, e.g., the devices that are 
critical in the production process—incubators. A monitoring system is installed 
in the rooms. It monitors the environment and notifies employees supervising cell 
cultures about the occurrence of errors in the culture process. Such monitoring is 
necessary because it allows for quick response and taking action in the event of a 
risk of culture loss.
Highly specialized persons who have acquired appropriate skills in numer-
ous training sessions are assigned to work in the clean rooms. Their professional 
experience and the ability to organize and manage their working time are also 
important. Due to the specifics of the work—a sterile, monitored and supervised 
environment in a clean room—each entrance to such rooms generates additional 
costs. That is why, employees working with cell cultures must carefully consider, 
plan, and organize all elements of their work in the laboratory before it begins. 
Employees involved in the preparation of cell cultures follow the applicable, written 
procedures and validated processes. Most processes should be validated based on 
reference reagents; however, the tissue material from which the cells are isolated 
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and the culture is established is so unique that it is not possible to replace it with 
the reference material. Therefore, all employees must comply with specific require-
ments. In standard work, it is important not only to maintain the purity and sterility 
of the cell culture and the rooms but also to ensure that all necessary reagents and 
materials are available in the laboratory. The duty of employees leaving the labora-
tory is to supplement, prepare, or provide information on missing items to all 
persons involved in the cell culture process. Each employee entering the laboratory 
studio must be sure that he or she will be able to perform all the tasks without any 
problems. Due to the need to monitor and maintain room sterility, any unneces-
sary entering and exiting the clean room creates a risk of pollution and generates 
costs of, among other things, used protective clothing and cleaning agents. All 
these activities are aimed at ensuring the sterility of the advanced therapy medici-
nal product manufactured in the tissue bank. Figure 2 shows the increase in the 
number of cultures and autologous skin cell transplantations. This increase has 
been possible thanks to the standardization of production processes that has been 
achieved by minimizing material losses. The lean and TOC management methods 
contributed to the increase in the number of cultures, which made better manage-
ment of laboratory resources possible.
As mentioned above, cell cultures can be established after the occurrence of a 
mass event, e.g., an explosion in a coal mine or a large fire, in which more people 
suffer burns. In such a situation, our only safeguard that makes it possible to take 
appropriate action is to keep reagents and consumables in the laboratory. In such 
cases, the experience of employees and cooperation with other hospital depart-
ments are very important. This allows for the planning of a strategic approach to the 
problem, which goes beyond the GMP management area, and still requires manage-
ment and control. Establishing a cell culture is conditioned not only by securing the 
necessary reagents and materials but also by providing care for the most disadvan-
taged patients, which results from the efficient operation of the hospital, reinforced 
by the management system. In such cases, it is also important to adopt the right 
approach and plan the work of all personnel to avoid unwanted cross-infection or 
contamination, which could result in the loss of valuable cell culture. The resource-
based view (RBV) approach seems to be necessary to manage the aspects that are 
not covered by the GMP procedures.
The preparation of biostatic skin and human amnion grafts is much less 
restrictive. These are grafts, in which the final stage of preparation is radiation 
Figure 2. 
Number of cultured and transplanted autologous skin cell cultures in years 2008–2018.
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sterilization. This means that these transplants are not live and constitute only a 
temporary dressing. Due to the fact of sterilization, the grafts are also prepared 
in clean rooms, under the laminar chamber of class A air purity, but in the class 
C environment. When preparing tissue transplants, employees also use their 
experience in managing their working time, maintaining cleanliness and order 
in the laboratory and good manufacturing practice. These skills are very useful 
and promote continuous improvement of the produced grafts and production 
efficiency. The chart in Figure 3 shows the increase in the surface area of biostatic 
amniotic and dermal grafts prepared in particular years. The use of a resource 
management approach, among others, has enabled the increase in productivity, 
which translates into the surface area (cm2) of the prepared tissue and cellular 
grafts. The increasing number of donors, and hence the amount of documenta-
tion to complete, makes it necessary to adopt a strategic approach to the work so 
that as much work as possible can be performed at the same time, thus generating 
added value.
6.  Strategic potential of a tissue bank in terms of validation of processes 
and qualification of equipment and rooms
Tissue bank management requires well-established, thorough knowledge of the 
processes occurring in the area of clean room production. In this respect, the key 
issue for a tissue bank, as mentioned above, is to have adequately qualified person-
nel and therefore human resources possessing the required education, experi-
ence, competences, and abilities. The second important element in the process of 
managing a tissue bank is the possession of appropriate devices and rooms, i.e., 
the hardware and accommodation resources. User requirements for hardware and 
accommodation resources should be characterized and defined in detail. These 
elements, in the RBV approach, can be collectively referred to as strategic potential. 
In general terms, the strategic potential is a factor influencing the tissue bank’s 
achievement of the expected results. The key effects include the ability to use 
resources to achieve the intended targets and, therefore, obtain the highest quality 
product according to the tested, repeatable, and effective production methodology 
using adequately verified equipment and rooms.
Figure 3. 
The surface area of prepared skin and amniotic grafts in years 2009–2018.
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The expected effects are, therefore, the result of the tissue bank’s implementation 
of adequately planned tasks. These tasks are directly related to the achievement of 
the intended objective. In this respect, the achieved production effects are the so-
called determinants of a tissue bank success. We use this expression to appropriately 
define the ranges and criteria of acceptance that a given tissue bank product must 
meet before a batch is released to distribution. These criteria must be strictly defined 
in the production specification. Moreover, in addition to the so-called determinants 
of success, so-called success factors must also be defined. These factors result from 
adequately defined and purposefully adopted strategic potentials of the tissue bank. 
The strategic potentials include in particular the professional experience of human 
resources. Based on specific experience and “know-how,” appropriate operational 
procedures should be created for all activities performed in the tissue bank. However, 
the final adoption of all the proposed solutions (e.g., methodological, analytical, 
and technological) requires evaluation that is very carefully planned and analyzed in 
terms of the correctness of the adopted assumptions. This means that each parameter 
that constitutes a specific stage or the whole of a given process must be subject to con-
trol in terms of meeting the expected assumptions. In case of changes in the specified 
parameter or parameters, a whole evaluation of the process must be repeated.
Procedures related to the evaluation of processes executed in the tissue bank are 
called validation procedures. In this respect, special consideration should be given 
to the validation of the manufacturing process of the hospital-exemption advanced 
therapy medicinal product (HE-ATMP), the process of manufacturing medical 
devices, tissue transplants, transport of these products, cleaning, and disinfection, 
including employee clothing. However, by contrast, the evaluation procedures 
related to the correct functioning of devices and rooms are called qualification 
procedures. In this respect, it should be clearly emphasized that the qualification 
of devices and rooms covers the entirety of undertakings related to the purchase, 
installation, and operation of a given device or room, starting from specifying the 
user’s specific requirements to determining the conformity of the proposed prelimi-
nary design with the requirements, to subsequent processes confirming the compli-
ance regarding the installation and proper functioning.
6.1 Main validation plan
The main validation plan (MVP) defines the approach to the qualification/valida-
tion of GMP areas for all validation activities carried out in the existing or newly 
designed premises of a tissue bank. It is aimed at ensuring that the expectations have 
been clearly communicated to all participants implementing the validation program. 
The MVP clearly and comprehensively defines the requirements and scope of responsi-
bility in the validation process. The main objectives and tasks of the MVP are as follows:
1. Presentation of policy, requirements, and expectations regarding the valida-
tion activities in laboratory rooms where the tasks related to the production of 
advanced therapy medicinal products, HE-ATMP, analysis and quality control, 
as well as research and development work are performed
2. Defining the organizational structure of validation activities
3. A brief description of the installations, systems, and devices that will be 
validated with reference to the existing documents
4. Specification of the format of the validation documentation used in the 
protocols and reports
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5. Outlining the validation strategy and indicating the documents defining the 
task and scope of responsibility for the tissue bank, contractors and suppliers 
of particular systems, installations, and process equipment
6. Presentation of the approach to change control
7. Drawing up a plan and scheduling validation activities
8. Ensuring consistent application of the terms in accordance with their estab-
lished definitions (in documents such as the standard operating procedures 
(SOPs), validation protocols, etc.)
The MPV contains general guidelines for the preparation of other validation 
documents. Rational principles and a rational approach when using the MPV are 
recommended. In the event of circumstances unforeseen in the plan, the rationale 
and assessment of the deviation must be documented.
Validation/qualification activities will be carried out depending on the subject of 
validation/qualification and on the nature of the activities performed by the valida-
tion team appointed by the qualified/competent/responsible person to perform spe-
cific tasks. The validation team may consist of representatives of quality assurance, 
tissue bank user/manager, technical and technological experts, and quality control.
This approach to validation and carrying out validation work fulfills the regula-
tions and guidelines specified in the European Commission Directive 2003/94/
EC and the Regulation of the Minister of Health of October 1, 2008, on the 
requirements of good manufacturing practice (Journal of Laws 2008.184.1143) as 
amended. Validation is an action aimed at confirming, in a documented manner and 
in accordance with the principles of RBV and good manufacturing practice, those 
procedures, processes, devices, materials, activities, systems, and installations truly 
lead to planned results. This is achieved through the development of test plans, 
protocols, and procedures, as well as the implementation of the records made in the 
protocols and the documentation of the results obtained in the intermediate and 
final reports. The report is an approved written plan of the measurement, control, 
and methodology of testing and result documentation. The verification and valida-
tion of the qualification and validation documentation are performed in accordance 
with the internal procedure prior to the initiation of the qualification/validation 
activities. In any case, the validation activities performed by external companies 
must be supervised by an appropriate employee of the tissue bank and are subject 
to acceptance and approval by tissue bank employees. The same persons and the 
persons performing the tests (other than those included in the validation team) also 
check and approve the reports from a given qualification/validation phase following 
the tests, in order to confirm that the production environment, devices, and the 
process are indeed suitable for the production of HE-ATMP, medical devices, tissue 
grafts, etc., in the tissue bank and that they meet the requirements of good manu-
facturing practice. The full set of qualification and validation documents consists of 
protocols and test cards.
The installation qualification (IQ ) protocols pertaining to the equipment, instal-
lations, and clean rooms, similar to the operational qualification (OQ ) protocols of 
these systems, are developed for all critical modules of systems, installations, and 
devices.
The process qualification (PQ ) protocols are developed only for those systems, 
installations, or devices for which their operation data are necessary to verify the 
correctness of the process and for which long-term monitoring of their perfor-
mance is recommended (e.g., laminar chamber, CO2 incubator, bioreactor, and 
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refrigerator-freezer). Systems, installations, or devices for which PQ activities are 
necessary will be selected at the risk analysis (RA) stage. Any noncompliance with 
the conditions set out in the protocols encountered during the validation process 
will be recorded and evaluated. The registered nonconformities will be analyzed, 
and then the actions regarding the manner of further dealing with the noncon-
formities (e.g., the development of justification/explanation, making corrections, 
and then carrying out reclassification tests) will be defined. All such data will be 
documented and saved. The obtained results will be collected and presented in 
relevant reports after the completion of each qualification stage.
6.2 Approach to validation
Validation of rooms, devices, systems, and installations used in production 
carried out in the tissue bank constitutes a part of the quality assurance policy of 
the entire enterprise (tissue bank, hospital, and biotechnological or pharmaceuti-
cal company). Qualification/validation activities and the creation of appropriate 
documentation must be carried out in accordance with the qualification/validation 
schedule by tissue bank representatives, suppliers of installations, systems, process 
equipment, and/or contractors providing validation services. Supervision and coor-
dination of qualification/validation activities should be carried out by a tissue bank 
representative. Validation teams and validation contractors are required to develop 
a series of protocols to check all critical parameters of rooms, systems, installations, 
and devices in the tissue bank. The protocols will be implemented in accordance 
with the test methods presented in the protocols. Each protocol will be used to 
obtain documentation that will confirm the compliance of the system, installation, 
or device with the GMP guidelines. To qualify equipment, rooms, and installations, 
the documents obtained after carrying out the service activities can be used. All 
protocols and reports will be archived after their final approval.
It should be emphasized that conducting validation cannot negatively affect the 
production process. In addition, special attention should be paid to the timely per-
formance of validation work, and subsequent planned validation activities related 
to a given device, room, etc., should be carried out within the prescribed time 
limit. However, it is possible that the deadline of the next validation is not met. This 
disadvantageous situation may occur due to a number of possible occurrences that 
may affect the feasibility of performing validation work. The factors affecting the 
performed validation work time shift include, among others, production, sickness 
of the person performing the validation, mechanical failure, etc. The information 
about the validation time shift must be included in the validation protocol.
In order to summarize and approve the completion of individual stages of quali-
fication/validation activities, appropriate reports are prepared, which are checked 
and approved by appropriate persons. The report must include a summary of the 
qualification/validation course, a description of test results, and documented, 
explained, and evaluated nonconformities. After the approval of the report, if no 
critical nonconformities were found or all critical nonconformities were resolved, 
you are allowed to proceed to the next qualification/validation phase.
6.3 Summary
The activities related to the performance of validation/qualification activities are 
aimed at ensuring the highest quality of the tissue bank products being developed. 
They take place in accordance with RBV and with the optimal use of the strate-
gic potential of the laboratory. The approach to validation is part of the broadly 
understood RBV, which results from the conscious management of the unit using 
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knowledge and science. The validation and qualification activities are necessary to 
verify the adopted methods and the continuous improvement of processes. This, in 
turn, fits into modern management systems using the PDCA or DMAIC approach, 
based on a thorough analysis of a given process and a thorough problem solution. It 
should also be emphasized that the validation activities require the involvement of 
appropriately qualified personnel, which will contribute to ensuring high quality 
and safety of the obtained products.
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